OPKO Health Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (30)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“OPKO Health - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by OPKO Health. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“OPKO Health - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“OPKO Health - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by OPKO Health. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“OPKO Health - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. OPKO Health

  1.1 Business Overview

  1.2 OPKO Health Pipeline Overview

 

2. OPKO Health Cancer Drugs in Research Phase

  2.1 Vaccines - OPKO Health/Academia Sinica

 

3. OPKO Health Cancer Drugs in Preclinical Phase

  3.1 Anticancer Monoclonal Antibodies - MabVax/MSKCC

  3.2 Therapeutic Antibodies - Zebra Biologics

 

4. OPKO Health Cancer Drugs in Phase-I

  4.1 MVT 2163

  4.2 MVT 5873

 

5. OPKO Health Cancer Drugs in Phase-II

  5.1 TT 701

 

6. Discontinued in Cancer Drugs in Clinical Pipeline

  6.1 Short Interfering RNA-Based Therapeutics - Silence Therapeutics

  6.2 Anti-LCG Monoclonal Antibody – eXegenics

  6.3 Vitamin D Signal Amplifiers - OPKO Health

  6.4 Retinoic Acid Metabolism Inhibitors - Allergan/OPKO Health

  6.5 P450RAI Inhibitors - OPKO Health

  6.6 Vitamin A Signal Amplifiers - OPKO Health

  6.7 Breast Cancer Therapies - Transition Therapeutics

  6.8 WHIP 180

  6.9 Estrogen Receptor Peptide – eXegenics


Figure 1-1: OPKO Health Cancer Pipeline by Phase (%)

Figure 1-2: OPKO Health Cancer Pipeline by Phase (Number)